CDR2 and neoplasm: However, in vivo studies of anti-Yo antibody reactivity have shown that the CDRL2 protein is the main target of these antibodies as it is intensely expressed in the tumours associated with PCD; in these tumours, anti-Yo antibodies exhibit less affinity for the CDR2 protein [17,19].